SPRY (ARS Pharmaceuticals) 6-1 Month Momentum % : -27.52% (As of Apr. 02, 2025)

View and export this data going back to 2022. Start your Free Trial

What is ARS Pharmaceuticals 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2025-04-02), ARS Pharmaceuticals's 6-1 Month Momentum % is -27.52%.

The industry rank for ARS Pharmaceuticals's 6-1 Month Momentum % or its related term are showing as below:

SPRY's 6-1 Month Momentum % is ranked worse than
68.57% of 1473 companies
in the Biotechnology industry
Industry Median: -11.85 vs SPRY: -27.52

Competitive Comparison of ARS Pharmaceuticals's 6-1 Month Momentum %

For the Biotechnology subindustry, ARS Pharmaceuticals's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ARS Pharmaceuticals's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ARS Pharmaceuticals's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where ARS Pharmaceuticals's 6-1 Month Momentum % falls into.

Save Embed

;

Save Embed

;

ARS Pharmaceuticals (NAS:SPRY) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %

( Price 1-month ago

Price 6-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ARS Pharmaceuticals (NAS:SPRY) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

ARS Pharmaceuticals 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of ARS Pharmaceuticals's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

ARS Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARS Pharmaceuticals Inc (NAS:SPRY) » Definitions » 6-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

N/A

Address

11682 El Camino Real, Suite 120, San Diego, CA, USA, 92130

Website

https://www.ars-pharma.com

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

Executives

Laura Shawver	director, officer: Chief Executive Officer	1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Richard E Lowenthal	director, 10 percent owner, officer: President and CEO	12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Sarina Tanimoto	10 percent owner, officer: Chief Medical Officer	C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Justin Chakma	officer: Chief Business Officer	C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Brian Dorsey	officer: Chief Operating Officer	C/O SOMAXON PHARMACEUTICALS, INC., 10935 VISTA SORRENTO PARKWAY, SUITE 250, SAN DIEGO CA 92130
Eric Karas	officer: Chief Commercial Officer	C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
James E Flynn	director, 10 percent owner, other: Director by deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Kathleen D. Scott	officer: Chief Financial Officer	C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Peter A. Thompson	director	C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Ra Capital Healthcare Fund Lp	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Alexander A Fitzpatrick	officer: Chief Legal Officer	9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121
Orbimed Capital Gp Vi Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Brent L Saunders	director	2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033
Rajeev Dadoo	director	C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130